Volitionrx Ltd
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleos… Read more
Volitionrx Ltd (VNRX) - Net Assets
Latest net assets as of September 2025: $-35.95 Million USD
Based on the latest financial reports, Volitionrx Ltd (VNRX) has net assets worth $-35.95 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($6.45 Million) and total liabilities ($42.40 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-35.95 Million |
| % of Total Assets | -557.45% |
| Annual Growth Rate | N/A |
| 5-Year Change | -260.23% |
| 10-Year Change | -531.94% |
| Growth Volatility | 450.11 |
Volitionrx Ltd - Net Assets Trend (2004–2024)
This chart illustrates how Volitionrx Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Volitionrx Ltd (2004–2024)
The table below shows the annual net assets of Volitionrx Ltd from 2004 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-26.11 Million | -199.67% |
| 2023-12-31 | $-8.71 Million | -178.62% |
| 2022-12-31 | $-3.13 Million | -117.64% |
| 2021-12-31 | $17.72 Million | +8.77% |
| 2020-12-31 | $16.29 Million | +14.76% |
| 2019-12-31 | $14.20 Million | +16.95% |
| 2018-12-31 | $12.14 Million | +21.92% |
| 2017-12-31 | $9.96 Million | -52.97% |
| 2016-12-31 | $21.18 Million | +250.33% |
| 2015-12-31 | $6.04 Million | +1541.68% |
| 2014-12-31 | $368.18K | -45.91% |
| 2013-12-31 | $680.67K | -18.36% |
| 2012-12-31 | $833.79K | -23.43% |
| 2011-12-31 | $1.09 Million | +1052.82% |
| 2010-12-31 | $-114.29K | -6.27% |
| 2009-12-31 | $-107.54K | -12.11% |
| 2008-12-31 | $-95.92K | -22.48% |
| 2007-12-31 | $-78.32K | -39.30% |
| 2006-12-31 | $-56.23K | +22.91% |
| 2005-12-31 | $-72.94K | -13.91% |
| 2004-12-31 | $-64.03K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Volitionrx Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 22945205900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $96.10K | % |
| Other Comprehensive Income | $385.63K | % |
| Other Components | $204.15 Million | % |
| Total Equity | $-24.91 Million | 100.00% |
Volitionrx Ltd Competitors by Market Cap
The table below lists competitors of Volitionrx Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Acanthe Développement
PA:ACAN
|
$17.78 Million |
|
ParaZero Technologies Ltd. Ordinary Shares
NASDAQ:PRZO
|
$17.78 Million |
|
SEAL Incorporated Bhd
KLSE:4286
|
$17.79 Million |
|
Tah Kong Chemical Industrial
TWO:4706
|
$17.79 Million |
|
Thai Rung Union Car Public Company Limited
BK:TRU
|
$17.77 Million |
|
Applus Servicios Tecnologicos
MC:APPS
|
$17.77 Million |
|
SYSTEM1 GROUP LS-01
F:BBA
|
$17.77 Million |
|
Eildon Capital Group
AU:EDC
|
$17.75 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Volitionrx Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -7,802,255 to -24,907,620, a change of -17,105,365.
- Net loss of 26,967,836 reduced equity.
- New share issuances of 8,592,177 increased equity.
- Other comprehensive income increased equity by 141,691.
- Other factors increased equity by 1,128,603.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-26.97 Million | -108.27% |
| Share Issuances | $8.59 Million | +34.5% |
| Other Comprehensive Income | $141.69K | +0.57% |
| Other Changes | $1.13 Million | +4.53% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Volitionrx Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-12-31 | $-0.05 | $0.19 | x |
| 2005-12-31 | $-0.06 | $0.19 | x |
| 2006-12-31 | $-0.03 | $0.19 | x |
| 2007-12-31 | $-0.03 | $0.19 | x |
| 2008-12-31 | $-0.04 | $0.19 | x |
| 2009-12-31 | $-0.05 | $0.19 | x |
| 2010-12-31 | $-0.05 | $0.19 | x |
| 2011-12-31 | $0.19 | $0.19 | x |
| 2012-12-31 | $0.09 | $0.19 | x |
| 2013-12-31 | $0.06 | $0.19 | x |
| 2014-12-31 | $0.03 | $0.19 | x |
| 2015-12-31 | $0.34 | $0.19 | x |
| 2016-12-31 | $0.92 | $0.19 | x |
| 2017-12-31 | $0.38 | $0.19 | x |
| 2018-12-31 | $0.39 | $0.19 | x |
| 2019-12-31 | $0.36 | $0.19 | x |
| 2020-12-31 | $0.36 | $0.19 | x |
| 2021-12-31 | $0.34 | $0.19 | x |
| 2022-12-31 | $-0.05 | $0.19 | x |
| 2023-12-31 | $-0.11 | $0.19 | x |
| 2024-12-31 | $-0.29 | $0.19 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Volitionrx Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -2186.27%
- • Asset Turnover: 0.13x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-209.67%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | 0.00% | 0.00% | 0.00x | 0.00x | $-17.78K |
| 2005 | 0.00% | 0.00% | 0.00x | 0.00x | $-16.89K |
| 2006 | 0.00% | 0.00% | 0.00x | 0.00x | $-31.36K |
| 2007 | 0.00% | 0.00% | 0.00x | 0.00x | $-18.46K |
| 2008 | 0.00% | 0.00% | 0.00x | 0.00x | $-12.21K |
| 2009 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.06K |
| 2010 | 0.00% | 0.00% | 0.00x | 0.00x | $481.70 |
| 2011 | -239.54% | 0.00% | 0.00x | 2.06x | $-2.72 Million |
| 2012 | -489.69% | -7428.05% | 0.02x | 2.66x | $-4.17 Million |
| 2013 | -545.09% | 0.00% | 0.00x | 3.04x | $-3.78 Million |
| 2014 | -2230.85% | -55553.12% | 0.00x | 9.32x | $-8.25 Million |
| 2015 | -157.67% | 0.00% | 0.00x | 1.28x | $-10.13 Million |
| 2016 | -56.22% | 0.00% | 0.00x | 1.17x | $-14.02 Million |
| 2017 | -148.32% | 0.00% | 0.00x | 1.47x | $-15.76 Million |
| 2018 | -148.34% | 0.00% | 0.00x | 1.44x | $-19.22 Million |
| 2019 | -113.39% | -94168.55% | 0.00x | 1.50x | $-17.52 Million |
| 2020 | -124.55% | -151508.34% | 0.00x | 1.60x | $-21.99 Million |
| 2021 | -149.43% | -29782.49% | 0.00x | 1.53x | $-28.61 Million |
| 2022 | 0.00% | -9879.11% | 0.02x | 0.00x | $-30.01 Million |
| 2023 | 0.00% | -4555.53% | 0.03x | 0.00x | $-34.54 Million |
| 2024 | 0.00% | -2186.27% | 0.13x | 0.00x | $-24.48 Million |
Industry Comparison
This section compares Volitionrx Ltd's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Volitionrx Ltd (VNRX) | $-35.95 Million | 0.00% | N/A | $17.77 Million |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |